Abstract
Background Blood-based HIV self-testing represents an alternative for increasing screening among key populations or populations with difficult access. In Cameroon, very few studies, on the usability of HIV self-tests based on blood samples, have been carried out among these groups.
Objective The aim of this study was to assess the usability of blood-based HIV self-testing among men who have sex with men (MSM) and female sex workers (FSWs) in the cities of Yaoundé and Douala, Cameroon.
Materials and Methods An observational study was conducted in 17 Community-Based Organisations (CBOs), including 10 MSM and 07 FSWs in Yaoundé and Douala from 11 to 22 June 2022. The study population consisted of HCV and MSM aged 21 years and over who agreed to participate in the study. After they were recruited consecutively in their respective CBOs, they received counselling, unassisted HIV blood self-testing and condoms. Data was collected using an administered questionnaire. Three HIV blood self-testing devices were used in the study: Mylan HIV Self-Test, Sure Check HIV Test® (Chembio Diagnostics Inc), Check Now HIV Self-Test(Abbott™ Point Of Care). Analysis was conducted using SPSS 23 software with a 95% confidence level.
Results Of 817 participants who completed the HIV blood self-test, just over half were TS 459(56.2%); the median age was 27 years (IQR: 22 years - 34 years) and the 25-49 age group was most represented 482(59.0%). One participant in ten (10%) had never been tested for HIV. However, 98.6% of participants agreed to use the HIV blood self-test and the vast majority (97.1%) followed the steps for carrying out the HIV blood self-test. An MSM was 4 times more likely to pass an HIV blood self-test than a TS (aOR= 4.01; 95% CI: 1.181-13.625; p=0.026). Similarly, TS and MSM who used the Abbott Check Now HIV Self-Test (aOR= 3.85; 95% CI: 1.246-11.908; p=0.019) and Chembio Sure Check HIV Test (aOR= 2.83; 95% CI: 1.072-7.720; p=0.036) were respectively 3.8 and 2.8 times and more likely to pass their self-test than those who used the Mylan blood self-test. Agreement between a participant’s HIV blood self-test result and Abbott-trained investigator-observers was moderate (κ=0.485; CI95% (0.359-0.610); p=0.001) while agreement with Chembio and Mylan was respectively low (κ=0.329; CI95% (0.203-0.454); p=0.001) and very low (κ=0.194; CI95%(0.05-0.329); p=0.001).
Conclusion HIV blood self-testing is acceptable and usable by key populations in Cameroon. Although usability was limited by problems in interpreting results and incorrect disposal of waste t by key populations, a blood-based HIV Self-Test, with moderate concordance, proved suitable for unassisted use in key populations, what could help improve HIV prevention interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was provided for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study obtained a favourable opinion from the National Ethics Committee for Human Health Research of Cameroon (reference numbers 2022/04/1448/CE/CNERSH/SP) and from the Operational Health Research Division of the Ministry of Health of Cameroon (Administrative Research Authorisation reference numbers 031-16-22). Written informed consent was obtained from study participants. All information collected was treated confidentially and stored within the limits permitted by law.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Competing interests: The authors have declared that no competing interests exist.
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
